502540689 10/22/2013

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2586122

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PIET HERDEWIJN	02/04/2011
CHRISTOPHE PANNECOUQUE	02/08/2011
TONGFEI WU	02/23/2011
ERIK DE CLERCQ	02/04/2011

RECEIVING PARTY DATA

Name:	K.U. LEUVEN RESEARCH & DEVELOPMENT
Street Address:	MINDERBROEDERSSTRAAT 8A - BUS 5105
City:	LEUVEN
State/Country:	BELGIUM
Postal Code:	B-3000

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	13940039	

CORRESPONDENCE DATA

Fax Number: (617)428-7045 Phone: 6174280200

Email: patentadministrator@clarkelbing.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: JAMES D. DECAMP Address Line 1: **CLARK & ELBING LLP** Address Line 2: 101 FEDERAL STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	50304-138003
NAME OF SUBMITTER:	JAN N. TITTEL

PATENT REEL: 031450 FRAME: 0685

502540689

Signature:	/Jan N. Tittel/
Date:	10/21/2013
Total Attachments: 2 source=50304_138003_Assignment#page1.tif source=50304_138003_Assignment#page2.tif	

PATENT REEL: 031450 FRAME: 0686

ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	City	State (and Country if not USA)
Piet HERDEWIJN	Wezemaal	Belgium
Christophe PANNECOUQUE	Heverlee	Belgium
Tongfei WU	Leuven	Belgium
Erik DE CLERCQ	Bierbeek	Belgium

hereby assign to

Full Name of Assignee	Country of Incorporation	Business Address
K.U. LEUVEN RESEARCH & DEVELOPMENT	Belgium	Groot Begijnhof Benedenstraat 58 B-3000 Leuven
	V	Belgium

and to its successors and assigns (collectively hereinafter called 'the Assignee'), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by us, identified as:

Title of Application	Filing Date	Serial Number
PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION	September 1, 2006	10/598,535

and we authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other freaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION Filing Date: September 1, 2006 U.S. Patent Application Serial No. 10/698.635

Piet HERDEWIJN

Christophe PANNECOUQUE

Tongfei WU

Erik DE CLERCO

4.02.204

Date

0802.2011

Date

28.02.2011

Date

04 Feb 2011

Date

Page 2 of 2